ClinicalTrials.gg
CompletedNCT06746064Updated Feb 12, 2026

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers and the Effect of Itraconazole on CHF10073 Exposure

A Phase 1 interventional study of CHF10073 (Part 1 - SAD) and Placebo (Part 1 - SAD) in Pulmonary Fibrosis, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies in Pulmonary Fibrosis with a site in Belgium — 4 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Fibrosis · Belgium.

Enrollment
13th of 18
155 · median 267
Started
2025
the only one that year
Phase 1
Only one
of the 21
Registered
19th of 21
by date
Lead sponsor
1 of 21
Chiesi Farmaceutici S.p.A.

Among the 21 studies in Pulmonary Fibrosis with a site in Belgium, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2025, is the only one in phase 1, and was the 19th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

4 of the 21 studies in Pulmonary Fibrosis with a site in Belgium are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Pulmonary Fibrosis with a site in Belgium, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety and tolerability of single ascending doses of inhaled CHF10073 (Part 1 of the study) and multiple ascending doses of CHF10073 (Part 2 of the study). The study will also evaluate the PK profile of study drug in plasma and urine after single and repeated administrations of CHF10073.

In addition, this study will also investigate the metabolites profile of CHF10073 in plasma, urine and faeces (Part 2 of the study) and the PK profile of CHF10073 in the lungs after bronchoalveolar lavage (BAL) (Part 3 of the study).

In addition, the effect of multiple doses of itraconazole on the pharmacokinetic profile of CHF10073 will be investigated (Part 4 of the study).

03

Conditions studied

  • Pulmonary Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject's written ;
  • Healthy male (Part 1 to 4) or female (Part 4) 18-55 years;
  • Understanding of the study procedures and the correct use of the inhalers;
  • between 18.5 and 30.0 kg/m2;
  • Non- or ex-smokers (\<5 pack-years and stopped smoking >1 year prior to screening);
  • Good physical and mental status;
  • Vital signs within normal limits; body temperature \<37.5°C;
  • 12-lead digitised in triplicate considered as normal;
  • Lung function measurements within normal limits;
  • Males with pregnant or non-pregnant women of (WOCBP) partners must be willing to use
  • Part 4 only: women of non-childbearing potential (WONCBP) or WOCBP with fertile male parters willing to use contraception

Exclusion criteria

Exclusion Criteria:

  • Recent participation in another clinical trial;
  • abnormal 24h Holter (Part 1 and 2);
  • Clinically relevant and uncontrolled medical disorders ;
  • Subjects with history of respiratory diseases ;
  • Presence of any current or recent infection;
  • Clinically relevant abnormal laboratory values;
  • Abnormal liver enzymes;
  • Positive results from the Hepatitis serology results;
  • Positive -1 or HIV-2 serology results ;
  • Recent blood donation or blood loss (≥450 mL) ;
  • Heavy caffeine drinker ;
  • Recent use of any kind of electronic smoking devices;
  • Documented history of alcohol abuse within 12 months prior to screening ;
  • Documented history of drug abuse within 12 months prior to screening ;
  • Intake of non-permitted concomitant medications ;
  • Known intolerance and/or to any of the study ;
  • Unsuitable veins for repeated venipuncture;
  • Part 3 only: to the BAL procedure;
  • Part 3 only: recent lower respiratory tract infections
  • Part 4 only: known allergy to antifungal medicines;
  • Part 4 and females only: pregnant or lactating women
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    CHF10073 active

    Drug: CHF10073 (Part 1 - SAD) · Drug: CHF10073 (Part 2 - MAD) · Drug: CHF10073 (Part 3) · Drug: CHF10073 (Part 4)

  • Placebo comparator
    placebo

    Drug: Placebo (Part 1 - SAD) · Drug: Placebo (Part 2 - MAD)

  • Experimental
    CHF10073 + itraconazole

    Drug: itraconazole (Part 4) · Drug: CHF10073 (Part 4)

Interventions

  • DrugCHF10073 (Part 1 - SAD)

    Single doses of CHF10073 for each cohort

  • DrugPlacebo (Part 1 - SAD)

    Single doses of placebo matching CHF10073 for each cohort

  • DrugCHF10073 (Part 2 - MAD)

    Multiple doses of CHF10073 for each cohort

  • DrugCHF10073 (Part 3)

    Single dose of CHF10073

  • DrugPlacebo (Part 2 - MAD)

    Multiple doses of placebo matching CHF10073 for each cohort

  • DrugItraconazoleStudies of ItraconazoleItraconazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Multiple dose of itraconazole in treatment period 2

  • DrugCHF10073 (Part 4)

    Single dose of CHF10073 in Treatment Period 1 and 2

06

What researchers measure

Primary outcomes

  1. Adverse events and adverse drug reactions

    Time frame: Through study completion, around 8 weeks in Part 1, from 10 to 13 weeks in Part 2, for about 7-8 weeks in Part 3 and for about 15 up to 17 weeks in Part 4

  2. Vital signs (Systolic and diastolic Blood Pressure)

    Time frame: From screening up to 42 days post-dose

  3. Absolute Values for 12-lead Electrocardiogram (ECG) Recording of HR (heart rate), HR from 0 to 24 hours, hourly HR

    Time frame: From screening up to 28 days post-dose

  4. Absolute Values for 12-lead ECGs Recording of Intervals

    Intervals recorded: PR, QRS, QT, QTcF

    Time frame: From screening up to 28 days post-dose

  5. Change from Baseline for Post-dose 12-lead ECGs Recording of HR, HR from 0 to 24 hours, hourly HR

    Time frame: From screening up to 28 days post-dose

  6. Change from Baseline for Post-dose 12-lead ECGs Recording of Intervals

    Intervals recorded: PR, QRS, QT, QTcF

    Time frame: From screening up to 28 days post-dose

  7. Number and percentage of subjects with abnormal actual QTcF (Fridericia-corrected QT Interval).

    Time frame: Part 1 and 2 only: From screening up to 28 days post-dose

  8. Number and percentage of subjects with abnormal change from the baseline of QTcF and HR from 0 to 24 hours

    Time frame: Part 1 and 2 only: From screening up to 28 days post-dose

  9. Number of subjects and percentages by treatment with abnormal parameters derived from 24h Holter ECG recording (total pauses >2.5 secs, atrial fibrillation and atrial flutter, ventricular runs, PAC burden, PVC burden and aberrant morphologies)

    Time frame: Part 1 and 2 only: From screening up to 28 days post-dose

  10. Number of subjects with abnormal blood laboratory test results

    Quantitative laboratory parameters (chemistry and haematology) will be summarised by treatment as absolute value and change from baseline using descriptive statistics.

    Time frame: From screening up to 28 days post-dose

  11. Number of subjects with abnormal urine laboratory test results

    Time frame: From screening up to 28 days post-dose

  12. Spirometry (FEV1 (Forced exhalation volume in the first second))

    Time frame: From screening up to 28 days post-dose

  13. Cough recording: percentage of days with cough episodes during the treatment period

    Time frame: Part 2 only: From first dosing up to 28 days post-dose

  14. Cough recording: average VAS (visual analogue scale))

    Time frame: Part 2 only: From first dosing up to 28 days post-dose

  15. CHF10073 plasma AUCt (Area Under the Curve from time 0 to time t)

    Time frame: From first dosing up to 42 days post-dose

  16. CHF10073 plasma Cmax (Maximum Plasma Concentration)

    Time frame: From first dosing up to 42 days post-dose

Secondary outcomes

  1. CHF10073 plasma AUCinf (Area Under the Curve from time 0 Extrapolated to Infinity)

    Time frame: From first dosing up to 42 days post-dose

  2. CHF10073 plasma tmax (Time to Maximum Plasma Concentration)

    Time frame: From first dosing up to 42 days post-dose

  3. CHF10073 plasma elimination half-life

    Time frame: From first dosing up to 42 days post-dose

  4. CHF10073 plasma apparent clearance (CL/F)

    Time frame: From first dosing up to 42 days post-dose

  5. CHF10073 plasma apparent volume of distribution (Vz/F)

    Time frame: From first dosing up to 42 days post-dose

  6. CHF10073 urine amount excreted (Ae)

    Time frame: Part 1, 2 and 4 : From first dosing up to 28 days post-dose

  7. CHF10073 urine faction excreted (fe)

    Time frame: Part 1, 2 and 4: From first dosing up to 28 days post-dose

  8. CHF10073 renal clearance (CLr)

    Time frame: Part 1, 2 and 4: From first dosing up to 28 days post-dose

07

Study locations

1 site
  • SGS Belgium NV Clinical Pharmacology Unit
    Edegem, 2650, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Feb 2026, 12 months.

Of 20 phase 1 interventional studies under Pulmonary Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 55. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Dec 24, 2024
StartActual
Jan 13, 2025
Primary completionActual
Feb 4, 2026
CompletionActual
Feb 4, 2026
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06746064
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Jan 13, 2025
Primary completion
Feb 4, 2026
Completion
Feb 4, 2026
Last update
Feb 12, 2026

Study contacts

Jelle Klein, MD
principal investigator · SGS Belgium

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion